A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group

Circulation. 1990 Jun;81(6):1753-61. doi: 10.1161/01.cir.81.6.1753.

Abstract

A multicenter, double-blind, placebo-controlled trial was conducted to determine if corticosteroids influence the development of restenosis after successful percutaneous transluminal coronary angioplasty (PTCA). Either placebo or 1.0 g methylprednisolone (steroid) was infused intravenously 2-24 hours before planned PTCA in 915 patients. The PTCA patient success rate was 87% (mean) in the eight centers. There were no differences in clinical or angiographic baseline variables between the two groups. End-point analysis (angiographic restenosis, death, recurrent ischemia necessitating early restudy, and coronary artery bypass graft surgery) showed that there was no significant difference comparing placebo- with steroid-treated patients. Angiographic restudy showed the lesion restenosis rate to be 39% (120 of 307 lesions) after placebo and 40% (117 of 291) after steroid treatment (p = NS). We conclude that pulse steroid pretreatment does not influence the overall restenosis rate after successful PTCA.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Multicenter Study

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Combined Modality Therapy
  • Coronary Disease / pathology
  • Coronary Disease / therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Multicenter Studies as Topic
  • Multivariate Analysis
  • Premedication*
  • Recurrence
  • Risk Factors

Substances

  • Methylprednisolone